Indoco Remedies Limited has informed the Exchange regarding a press release dated May 28, 2026, titled "Indoco's formulation plant at Baddi (Plant III) receives EU GMP Certification".
INDOCO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Indoco Remedies has received EU GMP certification from the German Health Authority (Berlin) for its Oral Solid Dosage manufacturing facility (Plant III) located at Baddi, Himachal Pradesh. The inspection was conducted from April 22-27, 2026. This certification confirms the facility meets Good Manufacturing Practice requirements under the EC Directive. The company is a fully integrated pharma firm with US$ 175 million turnover and over 6,000 employees. This certification opens doors for Indoco to supply pharmaceutical products to European Union markets.
The EU GMP certification is a positive regulatory development that enhances Indoco's capability to export to European markets, which typically earn hard currencies. While no immediate orders are mentioned, this approval expands the company's addressable market and could support future revenue growth.